Cytokinetics (CYTK) News Today $37.35 -5.57 (-12.98%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$37.46 +0.10 (+0.28%) As of 05/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cytokinetics (NASDAQ:CYTK) Shares Gap Down on Analyst DowngradeCytokinetics (NASDAQ:CYTK) Shares Gap Down After Analyst DowngradeMay 5 at 2:53 AM | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Cytokinetics (NASDAQ:CYTK)May 5 at 2:47 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $72.00 price objective on shares of Cytokinetics in a research note on Friday.May 4 at 8:47 AM | marketbeat.comAllostery Investments LP Invests $3.06 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)Allostery Investments LP acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 65,000 shares of the biopharmaceutical company's sMay 4 at 7:45 AM | marketbeat.comVoya Investment Management LLC Increases Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Voya Investment Management LLC boosted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 14.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,463 shares of the biopharmaceutical company's stocMay 4 at 4:19 AM | marketbeat.comWhy Cytokinetics, Inc. (CYTK) Went Down On FridayMay 3 at 7:46 PM | msn.comEnvestnet Asset Management Inc. Has $1.24 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Envestnet Asset Management Inc. trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,455 shares of the biopharmaceuticMay 3 at 3:21 AM | marketbeat.comCYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law FirmMay 2 at 3:45 PM | businesswire.comCytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTKMay 2 at 1:25 PM | tmcnet.comCytokinetics stock falls on FDA delay for heart drugMay 2 at 8:25 AM | in.investing.comCytokinetics drops as FDA extends review period for lead drugMay 2 at 8:25 AM | msn.comCytokinetics Shares Fall After FDA Extends Review of Heart Drug AficamtenMay 1, 2025 | marketwatch.comFDA delays decision for Cytokinetics heart-failure drugMay 1, 2025 | bizjournals.comCytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic CardiomyopathyMay 1, 2025 | globenewswire.comCytokinetics (CYTK) Expected to Announce Quarterly Earnings on TuesdayCytokinetics (NASDAQ:CYTK) will be releasing its Q1 2025 earnings after the market closes on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-cytokinetics-incorporated-stock/)May 1, 2025 | marketbeat.comCytokinetics to Participate in May Investor ConferencesApril 30, 2025 | globenewswire.comSusquehanna Fundamental Investments LLC Makes New $6.20 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)Susquehanna Fundamental Investments LLC bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 131,799 shares of the biophApril 30, 2025 | marketbeat.comPinebridge Investments L.P. Increases Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Pinebridge Investments L.P. increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 42.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 36,404 shares of the biopharmaceutical company's stock aftApril 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $123.49 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Price T Rowe Associates Inc. MD lessened its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 17.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,625,081 shares of the biopharmaceutical company's stock after selling 539,864 sharesApril 30, 2025 | marketbeat.comMelqart Asset Management UK Ltd Sells 75,824 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Melqart Asset Management UK Ltd decreased its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 6.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,136,434 shares of the biopharmaceuticalApril 29, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Position Increased by Aquatic Capital Management LLCAquatic Capital Management LLC raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 131.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,553 shares of the bApril 29, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Boothbay Fund Management LLCBoothbay Fund Management LLC reduced its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,370 shares of the biopharmaceutical company's stock after selling 22,647 shApril 29, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Tower Research Capital LLC TRC increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 86.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,920 shares of the biopharmaceutical company's stock after buying an addApril 29, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by CANADA LIFE ASSURANCE CoCANADA LIFE ASSURANCE Co cut its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 14.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 76,460 shares of the biopharmaceutical company's sApril 28, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Research Coverage Started at BarclaysApril 27, 2025 | americanbankingnews.comJ. Safra Sarasin Holding AG Acquires Shares of 13,027 Cytokinetics, Incorporated (NASDAQ:CYTK)J. Safra Sarasin Holding AG bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,027 shares of the biopharmaceutical company's stock, valued at apApril 26, 2025 | marketbeat.comBarclays Initiates Coverage of Cytokinetics (CYTK) with Overweight RecommendationApril 25, 2025 | msn.comT. Rowe Price Investment Management Inc. Purchases 1,062,136 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)T. Rowe Price Investment Management Inc. boosted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 11.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,752,123 shares of the bApril 25, 2025 | marketbeat.comMetLife Investment Management LLC Has $6.29 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)MetLife Investment Management LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 8.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,702 shares of thApril 25, 2025 | marketbeat.comCytokinetics initiated with an Overweight at BarclaysApril 25, 2025 | markets.businessinsider.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the company's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $38.11, for a total transaction of $76,220.00. Following the transaction, the executive vice president now owns 140,255 shares of the company's stock, valued at $5,345,118.05. This trade represents a 1.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.April 24, 2025 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 20,000 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendall Wierenga sold 20,000 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $38.46, for a total transaction of $769,200.00. Following the sale, the director now owns 24,848 shares in the company, valued at approximately $955,654.08. This represents a 44.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.April 23, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research note on Monday.April 23, 2025 | marketbeat.comCapital International Investors Invests $51.56 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)Capital International Investors bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,096,164 shares of the biopApril 23, 2025 | marketbeat.comCytokinetics to Announce First Quarter Results on May 6, 2025April 22, 2025 | globenewswire.comWendall Wierenga Sells 20,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 22, 2025 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC trimmed its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 192,167 shares of the biopharmaceutical company's stock aftApril 20, 2025 | marketbeat.comMarshall Wace LLP Acquires 279,612 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Marshall Wace LLP boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,153,313 shares of the biopharmaceutical compApril 19, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $123,325.40 in StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director John T. Henderson sold 3,190 shares of Cytokinetics stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $38.66, for a total transaction of $123,325.40. Following the transaction, the director now owns 66,348 shares of the company's stock, valued at $2,565,013.68. This represents a 4.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.April 18, 2025 | marketbeat.comIs Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?April 18, 2025 | msn.comCytokinetics Inc (CYTK) Announces Stock Options and RSUs for New Employees | CYTK stock newsApril 17, 2025 | gurufocus.comCytokinetics Inc (CYTK) Announces Stock Options and RSUs for New Employees | CYTK stock newsApril 17, 2025 | gurufocus.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2025 | globenewswire.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $54.00 at Bank of AmericaBank of America lowered their target price on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating on the stock in a report on Tuesday.April 17, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Gap Down - What's Next?Cytokinetics (NASDAQ:CYTK) Shares Gap Down - Here's What HappenedApril 17, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK)HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a report on Tuesday.April 17, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 3,190 SharesApril 17, 2025 | insidertrades.comCytokinetics reiterated top pick after Bristol failure at H.C. WainwrightApril 15, 2025 | markets.businessinsider.comExodusPoint Capital Management LP Has $439,000 Position in Cytokinetics, Incorporated (NASDAQ:CYTK)ExodusPoint Capital Management LP lessened its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 92.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,324 shares of the biopharmaceutical company's stock after selling 108,660 shApril 15, 2025 | marketbeat.comBristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With ItApril 14, 2025 | investors.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.610.73▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼2610▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Teva Pharmaceutical Industries News Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTK Stock Free CYTK Stock Alerts